Biotech

All Articles

Transgene's popular cancer injection flunks midphase test

.Transgene's curative vaccine candidate TG4001 has actually flunked a phase 2 solid tumor test. Howe...

Upstream swells IPO to $255M as it provides together with CAMP4

.Upstream Bio possesses puffy its IPO to $255 million as the business signs up with CAMP4 Rehabs tod...

Sanofi flunks MS study, dealing an additional blow to Denali deal

.Sanofi has stopped a phase 2 difficulty of Denali Therapeutics-partnered oditrasertib in multiple s...

Turnstone lays off 60%, shocks C-suite to stretch out cash money

.Turnstone Biologics is actually decreasing its own headcount by 60% and shocking its C-suite in ord...

Gilead quits on $15M MASH wager after mulling preclinical information

.In a year that has observed a permission as well as a boating of readouts for metabolic dysfunction...

Texas biotech axes cancer contract, pins hopes on being overweight

.Alaunos Rehabs is axing an agreement along with Precigen, giving up licensing legal rights to a cus...

Capricor portions much more records for DMD treatment after initiating BLA

.Capricor Therapeutics is actually taking a success tour for their phase 2 Duchenne muscular dystrop...

FDA spots Kezar lupus test in grip adhering to 4 individual fatalities

.The FDA has actually put Kezar Lifestyle Sciences' lupus test on grip after the biotech hailed 4 de...

Phase 3 Scholar Stone test reaches SMA goal, sending stockpile 200%

.A stage 3 trial of Intellectual Rock's vertebral muscle atrophy (SMA) applicant has hit its major e...

CAMP 4 is newest to eye IPO, while Upstream spells out $182M plan

.RNA biotech CAMP4 Therapeutics has actually marked out plans for a $67 thousand IPO, with inflammat...